Sonoma Pharmaceuticals, Inc.
SNOA
$5.09
$0.030.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.43% | 12.19% | 13.51% | 11.81% | -0.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.43% | 12.19% | 13.51% | 11.81% | -0.13% |
| Cost of Revenue | 18.30% | 10.43% | 14.80% | 1.24% | -5.18% |
| Gross Profit | 16.01% | 15.17% | 11.29% | 34.17% | 9.29% |
| SG&A Expenses | -1.98% | -2.83% | 5.28% | -9.06% | -13.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.99% | 3.22% | 10.07% | 1.58% | -1.90% |
| Operating Income | 21.62% | 21.08% | -0.54% | 21.24% | 6.42% |
| Income Before Tax | 31.13% | 42.22% | 26.86% | 38.59% | 19.87% |
| Income Tax Expenses | 2,470.59% | 380.61% | 128.57% | -200.00% | 43.33% |
| Earnings from Continuing Operations | 22.04% | 28.50% | 26.16% | 40.06% | 19.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.04% | 28.50% | 26.16% | 40.06% | 19.75% |
| EBIT | 21.62% | 21.08% | -0.54% | 21.24% | 6.42% |
| EBITDA | 21.66% | 21.06% | -1.05% | 21.94% | 7.25% |
| EPS Basic | 75.57% | 78.94% | 79.41% | 83.69% | 67.43% |
| Normalized Basic EPS | 77.65% | 82.09% | 79.23% | 83.02% | 68.63% |
| EPS Diluted | 75.57% | 78.94% | 79.41% | 83.69% | 67.43% |
| Normalized Diluted EPS | 77.65% | 82.09% | 79.23% | 83.02% | 68.63% |
| Average Basic Shares Outstanding | 137.49% | 172.97% | 225.63% | 266.16% | 214.34% |
| Average Diluted Shares Outstanding | 137.49% | 172.97% | 225.63% | 266.16% | 214.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |